Secretin - Sanochemia

Drug Profile

Secretin - Sanochemia

Alternative Names: Secrelux

Latest Information Update: 14 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanochemia Pharmazeutika
  • Class Antipsychotics; Gastrointestinal hormones; Neuropeptides; Peptide diagnostics; Peptide hormones
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pancreatic disorders; Zollinger-Ellison syndrome
  • Clinical Phase Unknown Pancreatitis

Most Recent Events

  • 14 Oct 2015 Clinical trials in Pancreatitis in Europe (IV) (Sanochemia pipeline, October 2015)
  • 14 May 2013 Sanochemia's porcine synthetic secretin licensed to LINK Healthcare in Australia, New Zealand, Japan, South Africa and Asia (excluding Philippines and South Korea)
  • 30 Sep 2005 No development reported - Clinical-Phase-Unknown for Pancreatitis in Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top